FindTrial
Sign In

Clinical study of BRCA1 and BRCA2 gene mutations in ovarian cancer in Shenzhen

Clinical study of BRCA1 and BRCA2 gene mutations in ovarian cancer in Shenzhen

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-COC-17010982
Enrollment
Unknown
Registered
2017-03-26
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mutation of BRCA1 and BRCA2 gene in ovarian cancer in Shenzhen

Interventions

BRCA positive group and BRCA negative group:5ml peripheral blood was extracted

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: The results showed that the pathological findings were epithelial ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma and endometrioid carcinoma

Exclusion criteria

Exclusion criteria: There were obvious cardiopulmonary dysfunction, can not participate in follow-up

Design outcomes

Primary

MeasureTime frame
BRCA genes;—

Countries

China

Contacts

Public ContactFang Guangguang

Shenzhen Second People's Hospital

Fgg0315@163.com+86 18988782968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026